SLC30A1 and Cognitive impairment: Post-mortem analyses have shown that ZNT1 expression is reduced in AD as well as in patients suffering from mild cognitive impairment.38 On the other hand, patients with fulminant AD displayed an increased expression of ZNT1. 38